ATE288447T1 - Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf) - Google Patents

Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)

Info

Publication number
ATE288447T1
ATE288447T1 AT96932325T AT96932325T ATE288447T1 AT E288447 T1 ATE288447 T1 AT E288447T1 AT 96932325 T AT96932325 T AT 96932325T AT 96932325 T AT96932325 T AT 96932325T AT E288447 T1 ATE288447 T1 AT E288447T1
Authority
AT
Austria
Prior art keywords
gdnf
cell line
glial cell
derived
treating alzheimer
Prior art date
Application number
AT96932325T
Other languages
English (en)
Inventor
Lawrence R Williams
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE288447T1 publication Critical patent/ATE288447T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96932325T 1995-09-28 1996-09-23 Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf) ATE288447T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/535,682 US5731284A (en) 1995-09-28 1995-09-28 Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
PCT/US1996/015305 WO1997011965A1 (en) 1995-09-28 1996-09-23 Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product

Publications (1)

Publication Number Publication Date
ATE288447T1 true ATE288447T1 (de) 2005-02-15

Family

ID=24135315

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96932325T ATE288447T1 (de) 1995-09-28 1996-09-23 Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)

Country Status (13)

Country Link
US (1) US5731284A (de)
EP (1) EP0852585B1 (de)
JP (1) JP4761409B2 (de)
AT (1) ATE288447T1 (de)
AU (1) AU711053B2 (de)
CA (1) CA2232789C (de)
DE (1) DE69634301T2 (de)
DK (1) DK0852585T3 (de)
ES (1) ES2237775T3 (de)
NZ (1) NZ319040A (de)
PT (1) PT852585E (de)
SI (1) SI0852585T1 (de)
WO (1) WO1997011965A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
WO1998052574A1 (en) * 1997-05-22 1998-11-26 Cephalon, Inc. Vitamin d analogues and their neuronal effects
ES2214743T3 (es) * 1997-09-19 2004-09-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Combinacion de citocinas con actividad neurotrofica.
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
AU758155B2 (en) 1998-04-29 2003-03-13 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
WO2000030670A1 (en) * 1998-11-20 2000-06-02 Yale University Effects of gdnf and ngf on sodium channels in drg neurons
HK1054680A1 (zh) 2000-05-05 2003-12-12 The Research Foundation Of The City University Of New York 通过调节精氨酸酶和多胺的合成刺激神经系统再生和修复的方法
AU2001278919A1 (en) 2000-07-13 2002-01-30 University Of South Florida Transgenic animal and methods
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
KR20050021026A (ko) * 2001-06-15 2005-03-07 주식회사 장생도라지 장생도라지 추출물을 포함하는 면역계의 이상으로부터발생하는 질병의 예방 및 치료용 약제학적 조성물
US7150737B2 (en) * 2001-07-13 2006-12-19 Sci/Med Life Systems, Inc. Methods and apparatuses for navigating the subarachnoid space
US7455666B2 (en) * 2001-07-13 2008-11-25 Board Of Regents, The University Of Texas System Methods and apparatuses for navigating the subarachnoid space
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004021992A2 (en) * 2002-09-06 2004-03-18 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US20040209810A1 (en) * 2003-02-24 2004-10-21 Gill Steven S. Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US20050225165A1 (en) * 2004-04-13 2005-10-13 Naik Sanjeev M Brake by-wire control system
GB2414934A (en) * 2004-06-11 2005-12-14 Gill Steven Streatfield Treatment of Parkinson's disease with GDNF
US8916165B2 (en) * 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
AR051528A1 (es) 2004-12-15 2007-01-17 Neuralab Ltd Anticuerpos humanizados que reconocen el peptido beta amiloideo
AR051800A1 (es) * 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
US20080286250A1 (en) * 2005-10-28 2008-11-20 Jens Tornoe Implantable Biocompatible Immunoisolatory Vehicle for Delivery of Gdnf
US20090181008A1 (en) * 2005-11-10 2009-07-16 Satoris, Inc. Methods of treating alzheimer's disease
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
SI2019683T2 (sl) 2006-04-25 2022-10-28 The Regents Of The University Of California Dajanje rastnih faktorjev za zdravljenje motenj CŽS
EP2023949A4 (de) * 2006-04-26 2009-08-26 Univ California Zusammensetzungen und verfahren für konvektionsverstärkte freisetzung von neurotherapeutika mit hohem molekulargewicht
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2291181B9 (de) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine zur Behandlung von depressionartigen Symptomen
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2485638B1 (de) 2009-10-07 2016-11-30 Endophys Holdings, LLC Medizinische druckerfassungsvorrichtungen
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
MX359070B (es) 2010-12-01 2018-09-13 Alderbio Holdings Llc Composiciones anti-ngf y uso de las mismas.
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US20140302027A1 (en) * 2011-09-26 2014-10-09 University Of Louisville Research Foundation, Inc. Methods of treating periodontal inflammation and periodontal bone loss
US8999927B2 (en) * 2012-04-02 2015-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glial cell line-derived neurotrophic factor (GDNF) compositions and use thereof
JP2019535267A (ja) 2016-11-10 2019-12-12 ケロス セラピューティクス インコーポレイテッドＫｅｒｏｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｇｄｎｆ融合ポリペプチド及びその使用方法
EP3628315A1 (de) 2018-09-28 2020-04-01 Université de Caen Normandie Kombination aus acetylcholinesterase-inhibitor und 5-ht4-rezeptoragonist als neuroprotektives mittel zur behandlung von neurodegenerativen krankheiten

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
EP0423980B1 (de) * 1989-10-16 2000-07-12 Amgen Inc. Stammzellenfaktor
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5202428A (en) * 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP3385040B2 (ja) * 1991-02-14 2003-03-10 武田薬品工業株式会社 グリア活性化因子およびその製造法
MX9205293A (es) * 1991-09-20 1993-05-01 Syntex Sinergen Neuroscience J Factores neurotrofico derivado del glial
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
JP4098355B2 (ja) * 1993-08-12 2008-06-11 ニューロテック ユーエスエー， インコーポレイテッド 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル
AU1443095A (en) * 1993-12-22 1995-07-10 University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
JP4761409B2 (ja) 2011-08-31
EP0852585B1 (de) 2005-02-02
PT852585E (pt) 2005-04-29
AU711053B2 (en) 1999-10-07
NZ319040A (en) 2001-02-23
CA2232789A1 (en) 1997-04-03
AU7117596A (en) 1997-04-17
CA2232789C (en) 2001-02-27
JPH11514860A (ja) 1999-12-21
US5731284A (en) 1998-03-24
DK0852585T3 (da) 2005-05-09
EP0852585A1 (de) 1998-07-15
SI0852585T1 (en) 2005-06-30
ES2237775T3 (es) 2005-08-01
WO1997011965A1 (en) 1997-04-03
DE69634301D1 (de) 2005-03-10
DE69634301T2 (de) 2005-06-09

Similar Documents

Publication Publication Date Title
ATE288447T1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
ATE194081T1 (de) Verfahren zur behandlung von verletzungen retinaler ganglione mit neurotrophischem faktor aus der glialzellinie (gdnf)
DE69913665D1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
LV10308A (lv) Ciliarais neirotropais faktors
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
ATE193020T1 (de) Verfahren zur herstellung von immunoglobulin g konzentrat
EP0268973A3 (de) Verfahren zur Herstellung eines virussicheren, lagerstabilen und intravenös verträglichen Immunglobulin-G-Präparates
DE3856580D1 (de) Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein
DE69029657D1 (de) Menschliches cytokin, interleukin-9
DE69810635D1 (de) Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust
ATE141613T1 (de) Prozess zur darstellung von aspartam aus einem diketopiperazin sowie neue zwischenprodukte und derivate dafür
DK0562508T3 (da) Nyt knogle-relateret protein OSF-2, fremgangsmåde til dets fremstilling samt farmaceutisk præparat med indhold deraf
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69607524D1 (de) Verfahren zur Herstellung von einem Bicyclohexanderivat
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
DE68903907D1 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
EP0237981A3 (de) Verfahren zur Herstellung eines den Blutgerinnungsfaktor VIII enthaltenden, sterilen Präparates
DE69014042D1 (de) Verfahren zur Herstellung von menschlichem Osteocalcin.
ATE263565T1 (de) Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten
DE69627379D1 (de) Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem
ATE13633T1 (de) Verfahren zur herstellung von hochgereinigtem antihaemophiliefaktor.
EP0238986A3 (de) Verfahren zur Herstellung eines den Blutgerinnungsfaktor VIII in ankonzentrierter Form enthaltenden Präparates
DE69122545D1 (de) Verfahren zur Herstellung von menschlichem Nervenwachstumsfaktor durch Genmanipulation
GR900100691A (el) Νευροτροφικός παράγοντας ακτινωτού.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0852585

Country of ref document: EP